TECHWIRE 30
(CIX: WRAL30)  1,085.92  up arrow+9.26  (0.86 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NQ: Apple)  105.22  up arrow+0.39  (0.37 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NY: QUINTILES)  57.56  up arrow+0.57  (1 %)  Updated: 06:40 PM EDT, Oct 24 2014
(OP: BASF SE)  87.22  down arrow-2.43  (-2.71 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NQ: BioCryst)  11.83  down arrow-0.36  (-2.95 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NQ: BioDelivery)  16.62  up arrow+0.24  (1.47 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NQ: CEMP)  12.46  up arrow+0.14  (1.14 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NQ: Cisco Systems)  23.78  up arrow+0.22  (0.91 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NQ: Cree)  29.67  up arrow+0.27  (0.92 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NQ: DARA)  0.87  down arrow-0.03  (-3.34 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NY: EMC CORPORATION)  28.17  up arrow+0.47  (1.7 %)  Updated: 06:40 PM EDT, Oct 24 2014
(NQ: Extreme Networks)  3.14  up arrow+0.02  (0.64 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NQ: FB)  80.67  up arrow+0.63  (0.79 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NY: GLAXOSMITHKLINE)  45.79  up arrow+0.43  (0.95 %)  Updated: 06:40 PM EDT, Oct 24 2014
(NQ: GOOG)  539.78  down arrow-4.2  (-0.77 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NY: IBM)  162.08  down arrow-0.1  (-0.06 %)  Updated: 06:40 PM EDT, Oct 24 2014
(NY: LH)  103.73  up arrow+1.05  (1.02 %)  Updated: 06:40 PM EDT, Oct 24 2014
(OP: Lenovo Group)  29.09  up arrow+0.07  (0.24 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NY: MRK)  57.61  up arrow+0.98  (1.73 %)  Updated: 06:40 PM EDT, Oct 24 2014
(NQ: Microsoft Corp)  46.13  up arrow+1.11  (2.47 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NQ: NTAP)  40.72  up arrow+0.42  (1.04 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NY: NOVARTIS AG)  90.15  up arrow+0.91  (1.02 %)  Updated: 06:40 PM EDT, Oct 24 2014
(OP: Novozymes A/S)  44.71  up arrow+0.17  (0.38 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NY: PFIZER)  29.11  up arrow+0.51  (1.78 %)  Updated: 06:40 PM EDT, Oct 24 2014
(NQ: Pozen)  8.75    (0 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NY: RED HAT)  56.02  up arrow+0.51  (0.92 %)  Updated: 06:40 PM EDT, Oct 24 2014
(NQ: BBRY)  10.26  down arrow-0.06  (-0.53 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NQ: Salix)  140.42  up arrow+4.86  (3.59 %)  Updated: 08:10 PM EDT, Oct 24 2014
(NQ: SQI)  15.60  up arrow+0.08  (0.52 %)  Updated: 08:10 PM EDT, Oct 24 2014

Posts tagged “Inspire”

September 8, 2011

Premium Lock Drutz to chair Gentris board

Gentris The company said Dr. David J. Drutz has been elected chairman, and entrepreneur and accountant Tim Gupton has joined the board.

June 30, 2011

Premium Lock Merck to close former Inspire HQ in Raleigh, cut 51 workers

Merck  The drug giant recently purchased Raleigh-based Inspire Pharmaceuticals. In a notice filed with the state, the expected closure of Inspire's offices is made official.

May 17, 2011

Premium Lock Merck wraps up $430M Inspire deal, will close Raleigh HQ

Merck  Some company executives will be leaving the eye drug firm as it is absorbed by the pharmaceutical giant.

Updated May 10, 2011

Premium Lock Inspire reports $17.6M quarterly loss after restructuring

Inspire eye drug fails Phase II trials The Raleigh-based pharmaceutical firm, which is in the process of being acquired by drug giant Merck, says losses increased nearly $3 million from a year ago.

Updated April 6, 2011

Premium Lock Merck's $430M buy triggers Inspire stock frenzy

Merck  Merck will pay $5 a share for Inspire. Both boards and a major Inspire investor have already approved the deal. Inspire's shares collapsed in January after a failed drug trial.

March 18, 2011

Premium Lock Tech briefs: Inspire Pharmaceuticals, Dex One, Nexxus Lighting, NC toll road devices

Tech Briefs Inspire offers bonuses; Dex One seeks feedback on executive pay; Lowes to sell Nexxus LED lighting; NC toll roll RFID devices clear tests.

February 17, 2011

Premium Lock Inspire drops lung drug, cuts 65 positions

Inspire Pharmaceuticals Inspire Pharmaceuticals said Thursday that it is laying off 65 people, or 27 percent of its work force related to the drug's development.

January 4, 2011

Premium Lock Analyst cuts Inspire after failed clinical trial

Inspire Shares in the Raleigh-based pharmaceutical firm plunged Monday on news of a failure for its drug targeting cystic fibrosis.

Updated January 3, 2011

Premium Lock Meltdown: Inspire Pharmaceutical shares down 59%

Inspire The company, which just moved to Raleigh, says its candidate for treatment of cystic fibrosis fails to meet efficacy goals in Phase III clinical trial.

December 13, 2010

Premium Lock $1.25M payday for Inspire - Dry eye drug launches in Japan

Inspire The Durham-based pharmaceutical firm's partner in Japan receives approval to launch Diquas. That news triggers a milestone payment plus future royalties.

Updated November 4, 2010

Premium Lock Inspire cuts losses, beats Street expectations

Inspire The Durham-based pharmaceutical firm loses far less than forecast - 9 cents per share rather than 14 cents as expected.

Updated August 25, 2010

Premium Lock Inspire, Allergan revise licensing agreement for eye drugs

Inspire The Durham-based firm regains control of failed drug candidate Prolacria. Inspire also will receive smaller royalties from Allegran for sales of eye drug Restasis.

May 3, 2010

Premium Lock Inspire cuts losses, bettering Wall Street expectations

Inspire sales climb Durham-based pharmaceutical firm reduces losses by $4.6 million from a year ago as eye drug sales surge.

Updated March 15, 2010

Premium Lock Failed drug trial news sends Inspire shares down 6%

Inspire eye drug fails Phase II trials Shares at pharmaceutical firm stage a comeback from a 13 percent drop at the open. Inspire says it will continue researching possible use of its pink eye drug AzaSite to treat another eye condition.

March 4, 2010

Premium Lock Revenue growth helps Inspire Pharmaceuticals beat Street expectations

Inspire Durham-based pharmaceutical firm reports a lower than expected quarterly loss.

February 24, 2010

Premium Lock Inspire’s new CEO receives 1 million stock options in taking job

Adrian Adams Adrian Adams receives 25% of the options immediately, including nearly 90,000 at $6.35 per share which was the closing price on his first day as the new boss. He replaced Christy Shaffer as of Monday.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Scroll